Biomarkers play a key role in the prevention, diagnosis, drug response and drug development of psychiatric disorders. Ace Therapeutics employs an integrated approach, combining animal models of disease with molecular biology techniques, multi-omics technologies, and imaging techniques, to assist clients in discovering, characterizing, and validating different biomarkers associated with psychiatric disorders. Our objective is to provide reliable, validated, and widely used biomarkers for psychiatric disorders and their therapeutic development through an integrated portfolio of services.

What Are Biomarkers?

A biomarker "is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to an intervention". Biomarkers can be used to make a diagnosis, to stage an illness, to predict diagnostic conversion or estimate prognosis, or to predict and monitor clinical response to treatment.

Fig. 1 Aims and examples of the main types of biomarkers. (García, M. S. et al., 2020)

The Main Types of Biomarker Identification We Offer

The identification of biomarkers in psychiatry is critical to facilitate diagnosis and treatment through the development of markers. Biomarkers can fulfill multiple criteria for different uses or present specific characteristics that enable their particular use. Ace Therapeutics offers the following types of biomarker identification and research services, depending on the application of the biomarker:

• Identification of diagnostic biomarker of psychosis
• Identification of pharmacodynamic or response biomarker of psychosis
• Identification of predictive biomarker of psychosis
• Identification of prognostic biomarker of psychosis
• Identification of susceptibility or risk biomarker of psychosis

Our Approach and Technologies

Ace Therapeutics offers a variety of technologies to help clients rapidly discover and characterize potential biomarkers for psychiatric disorders. Our identification methods and common technologies include, but are not limited to, the following:

• Molecular biology techniques (PCR, immunohistochemistry techniques)
• Histologic techniques (genetics, proteomics, metabolomics and epigenetics)
• Imaging techniques (magnetic resonance imaging (MRI), computed tomography (CT), dual-energy X-ray absorptiometry (DXA), transmission electron microscopy (TEM), scanning electron microscopy (SEM), positron emission tomography (PET), single photon emission computed tomography (SPECT), functional ultrasound (fUS) imaging, functional near-infrared spectroscopy (fNIRS))
• Biochemical techniques (metabolite determination in blood or cerebrospinal fluid samples)

Identification of Biomarkers of Psychiatric Disorders Service Process

Ace Therapeutics offers a customized one-stop services for biomarker identification of psychiatric disorders, and our service process includes the following key processes:

• Project consultancy and program customization

Our team of experienced project specialists develops biomarker research protocols for psychiatric disorders tailored to the specific disease under investigation and the objectives of the study.

• Animal modeling

We Provide customized animal models of psychiatric disorders based on customers' demands.

• Sample collection and establishment

We will work with you to identify the most suitable biological samples for biomarker analysis, such as blood, cerebrospinal fluid or tissue samples.

• Biomarker analysis

Comprehensive data analysis provides insights for subsequent diagnosis of psychiatric disorders and development of therapies.

Ace Therapeutics is dedicated to providing comprehensive services and support to assist clients in identifying biomarkers associated with psychiatric disorders. If you are interested in our services, please contact us. Our team of experts will contact you within one business day to discuss your demands.

Reference

1. García, M. S.; et al. Biomarkers in psychiatry: concept, definition, types and relevance to the clinical reality. Frontiers in psychiatry. 11 (2020): 527209.